Cargando…
Molnupiravir: First Approval
Molnupiravir (Lagevrio(®)) is an orally-administered antiviral prodrug that inhibits replication of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback Biotherapeutics for the prevention and treatment of Coronavirus disease 2019 (COVID-19). Molnupiravir received i...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858220/ https://www.ncbi.nlm.nih.gov/pubmed/35184266 http://dx.doi.org/10.1007/s40265-022-01684-5 |